
Maria Lycke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3052033/publications.pdf

Version: 2024-02-01



MADIALVCKE

#	Article	IF	CITATIONS
1	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 855-871.	2.8	8
2	Next Generation Plasma Proteomics Identifies High-Precision Biomarker Candidates for Ovarian Cancers, 2022, 14, 1757.	3.7	12
3	Consideration should be given to smoking, endometriosis, renal function (eGFR) and age when interpreting CA125 and HE4 in ovarian tumor diagnostics. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1954-1962.	2.3	21
4	Increased Diagnostic Accuracy of Adnexal Tumors with A Combination of Established Algorithms and Biomarkers. Journal of Clinical Medicine, 2020, 9, 299.	2.4	7
5	High throughput proteomics identifies a high-accuracy 11 plasma protein biomarker signature for ovarian cancer. Communications Biology, 2019, 2, 221.	4.4	77
6	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Science Translational Medicine, 2018, 10, .	12.4	178
7	A two-step strategy for identification of plasma protein biomarkers for endometrial and ovarian cancer. Clinical Proteomics, 2018, 15, 38.	2.1	20
8	Evaluation of Liquid From the Papanicolaou Test and Other Liquid Biopsies for the Detection of Endometrial and Ovarian Cancers. Obstetrical and Gynecological Survey, 2018, 73, 463-464.	0.4	3
9	A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecologic Oncology, 2018, 151, 159-165.	1.4	62